1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Bristol Likes What It Sees In Five Prime, Invests More In CSF1R Program

 
• By Jessica Merrill

Bristol-Myers Squibb Co. is upping its commitment to Five Prime Therapeutics Inc. and the antibody developer’s colony stimulating factor 1 receptor (CSF1R) antibody program with a new global licensing deal announced Oct. 15.

The deal replaces an existing clinical collaboration between the two companies signed in November 2014 to study Five Prime’s lead...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

 
• By Alaric DeArment

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

AstraZeneca And Daiichi Sankyo’s Datroway Scores Survival Success In TNBC

 
• By Andrew McConaghie

Its overall survival win for Datroway could be an advantage over Gilead’s Trodelvy in triple negative breast cancer.

Jazz Looks To Label Expansion To Reverse Zepzelca Sales Slump

 
• By Alaric DeArment

The FDA approved the drug for combination with Roche’s Tecentriq in first-line maintenance of extensive-stage small cell lung cancer, while the NCCN added the combination to its treatment guidelines.

Attractiveness of Cell Therapy In The Spotlight With Limited Interest In Galapagos Unit

 
• By Kevin Grogan

Non-binding offers have come mostly from groups of financial investors rather than biopharma players.

More from Therapy Areas

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.